



Financial Tear Sheet

Corporate Profile

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases.

Stock Information

EBS (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$66.16
Change (%)	▲ 1.15 (1.77%)
Volume	295,313
52 Week Low	\$46.49
Market Cap	\$3,370,524,905
Rolling EPS	1.96
PE Ratio	33.2396
Shares Outstanding	50,945,056

Data as of 02/15/19 4:02 p.m. ET



Recent Headlines & Events

02/12/19

Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors

02/07/19

Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019

01/24/19

Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors

SEC Filings

Filing Date	Form
02/12/19	8-K
02/11/19	SC 13G/A
02/08/19	SC 13G/A
01/28/19	SC 13G/A

Data provided by Nasdaq. Minimum 15 minutes delayed.

Date	Title
02/21/19 5:00 p.m. ET	Q4 2018 Emergent BioSolutions Inc. Earnings Conference Call

Primary IR Contact

Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (240) 631 3280
Fax: (240) 413-1917
E-mail: burrowsr@ebsi.com